JP2022521173A - 癌治療 - Google Patents

癌治療 Download PDF

Info

Publication number
JP2022521173A
JP2022521173A JP2021547154A JP2021547154A JP2022521173A JP 2022521173 A JP2022521173 A JP 2022521173A JP 2021547154 A JP2021547154 A JP 2021547154A JP 2021547154 A JP2021547154 A JP 2021547154A JP 2022521173 A JP2022521173 A JP 2022521173A
Authority
JP
Japan
Prior art keywords
eldaphytinib
specifically
cancer
daily
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021547154A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020165181A5 (enExample
Inventor
エリザベス オハガン，アン
ポール，ピーター マリー ゼット． デ
ナラヤン アヴァダニ，アンジャリ
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2022521173A publication Critical patent/JP2022521173A/ja
Publication of JPWO2020165181A5 publication Critical patent/JPWO2020165181A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021547154A 2019-02-12 2020-02-11 癌治療 Withdrawn JP2022521173A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19156806 2019-02-12
EP19156806.2 2019-02-12
EP19176575 2019-05-24
EP19176575.9 2019-05-24
PCT/EP2020/053490 WO2020165181A1 (en) 2019-02-12 2020-02-11 Cancer treatment

Publications (2)

Publication Number Publication Date
JP2022521173A true JP2022521173A (ja) 2022-04-06
JPWO2020165181A5 JPWO2020165181A5 (enExample) 2023-02-21

Family

ID=69467563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547154A Withdrawn JP2022521173A (ja) 2019-02-12 2020-02-11 癌治療

Country Status (16)

Country Link
US (1) US20220168298A1 (enExample)
EP (1) EP3923942A1 (enExample)
JP (1) JP2022521173A (enExample)
KR (1) KR20210126654A (enExample)
CN (1) CN113423402A (enExample)
AU (1) AU2020223467B2 (enExample)
BR (1) BR112021015686A2 (enExample)
CA (1) CA3126959A1 (enExample)
IL (1) IL285466A (enExample)
JO (1) JOP20210216A1 (enExample)
MA (1) MA54932A (enExample)
MX (1) MX2021009670A (enExample)
PH (1) PH12021551949A1 (enExample)
SG (1) SG11202107850VA (enExample)
TW (1) TWI863962B (enExample)
WO (1) WO2020165181A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117083283A (zh) * 2020-12-11 2023-11-17 医睿世康药业研发公司 用于癌症治疗的联合疗法
JP2023553533A (ja) * 2020-12-11 2023-12-21 エラスカ，インク． 癌の処置のための併用療法
CN112957368A (zh) * 2021-04-02 2021-06-15 南昌大学 一种司维拉姆的新用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018141921A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113957146A (zh) * 2014-09-26 2022-01-21 詹森药业有限公司 使用fgfr突变基因组鉴定将对用fgfr抑制剂进行治疗有反应的癌症患者
JOP20200201A1 (ar) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2017070708A1 (en) * 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018141921A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 11, JPN7024000154, 2010, pages 1850 - 1855, ISSN: 0005701164 *

Also Published As

Publication number Publication date
SG11202107850VA (en) 2021-08-30
TW202045173A (zh) 2020-12-16
US20220168298A1 (en) 2022-06-02
AU2020223467A1 (en) 2021-08-05
JOP20210216A1 (ar) 2023-01-30
CA3126959A1 (en) 2020-08-20
EP3923942A1 (en) 2021-12-22
PH12021551949A1 (en) 2022-07-18
KR20210126654A (ko) 2021-10-20
AU2020223467B2 (en) 2025-12-04
MA54932A (fr) 2021-12-22
BR112021015686A2 (pt) 2021-10-26
CN113423402A (zh) 2021-09-21
IL285466A (en) 2021-09-30
MX2021009670A (es) 2021-09-08
TWI863962B (zh) 2024-12-01
WO2020165181A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
JP7668777B2 (ja) 癌治療
TWI798199B (zh) 癌症治療
TWI816881B (zh) 用於治療三陰性乳癌之組合療法
JP2024516972A (ja) Ｒａｆ阻害薬による癌の処置
JP2022521173A (ja) 癌治療
JP2025156297A (ja) 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
JP2022527702A (ja) 小細胞肺がんの治療におけるキアウラニブの使用
WO2023212071A1 (en) Combination and the use thereof
HK40103983A (en) Cancer treatment
US20240034742A1 (en) Dosing regimens for cyclin-dependent kinase 7 (cdk7) inhibitors
HK40013982A (en) Cancer treatment
WO2023209611A1 (en) Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib
HK40018978B (en) Cancer treatment
HK40018978A (en) Cancer treatment
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250317

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250929

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20251015